{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T16:46:40Z","timestamp":1732034800180},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10637-013-0060-7","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T06:34:54Z","timestamp":1388990094000},"page":"500-509","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Phase I study of elisidepsin (Irvalec\u00ae) in combination with carboplatin or gemcitabine in patients with advanced malignancies"],"prefix":"10.1007","volume":"32","author":[{"given":"Francois","family":"Goldwasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinthya","family":"Coronado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen M.","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar Garc\u00eda","family":"Paramio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Luis Iglesias","family":"Dios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Miguel-Lillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"issue":"19","key":"60_CR1","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1021\/jo960877+","volume":"61","author":"MT Hamann","year":"1996","unstructured":"Hamann MT, Otto CS, Scheuer PJ, Dunbar DC (1996) Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet bryopsis sp. (1). J Org Chem 61(19):6594\u20136600","journal-title":"J Org Chem"},{"issue":"7","key":"60_CR2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/00001813-200108000-00003","volume":"12","author":"RW Sparidans","year":"2001","unstructured":"Sparidans RW, Stokvis E, Jimeno JM, Lopez-Lazaro L, Schellens JH, Beijnen JH (2001) Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F. Anti-Cancer Drugs 12(7):575\u2013582, Epub 2001\/08\/07","journal-title":"Anti-Cancer Drugs"},{"key":"60_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/978-3-540-30880-5_16","volume":"43","author":"G Faircloth","year":"2006","unstructured":"Faircloth G, Cuevas C (2006) Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363\u2013379, Epub 2006\/12\/13","journal-title":"Prog Mol Subcell Biol"},{"issue":"4","key":"60_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3816\/CLC.2009.n.041","volume":"10","author":"M Provencio","year":"2009","unstructured":"Provencio M, Sanchez A, Gasent J, Gomez P, Rosell R (2009) Cancer treatments: can we find treasures at the bottom of the sea? Clin Lung Cancer 10(4):295\u2013300","journal-title":"Clin Lung Cancer."},{"issue":"23","key":"60_CR5","doi-asserted-by":"publisher","first-page":"9779","DOI":"10.1158\/0008-5472.CAN-08-1981","volume":"68","author":"AB Herrero","year":"2008","unstructured":"Herrero AB, Astudillo AM, Balboa MA, Cuevas C, Balsinde J, Moreno S (2008) Levels of SCS7\/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res 68(23):9779\u20139787","journal-title":"Cancer Res"},{"issue":"4","key":"60_CR6","doi-asserted-by":"publisher","first-page":"e19042","DOI":"10.1371\/journal.pone.0019042","volume":"6","author":"JM Molina-Guijarro","year":"2011","unstructured":"Molina-Guijarro JM, Macias A, Garcia C, Munoz E, Garcia-Fernandez LF, David M et al (2011) Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS One 6(4):e19042","journal-title":"PLoS One"},{"issue":"16","key":"60_CR7","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1158\/1078-0432.CCR-10-1948","volume":"17","author":"YH Ling","year":"2011","unstructured":"Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J et al (2011) PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt\/mTOR signaling pathway, and activation of death-associated protein kinase. Clin Cancer Res Off J Am Assoc Cancer Res 17(16):5353\u20135366, Epub 2011\/06\/22","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"3","key":"60_CR8","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/md11030944","volume":"11","author":"M Serova","year":"2013","unstructured":"Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M et al (2013) Predictive factors of sensitivity to elisidepsin, a novel kahalalide f-derived marine compound. Marine Drugs 11(3):944\u2013959, Epub 2013\/03\/23","journal-title":"Marine Drugs"},{"key":"60_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1358\/dof.2010.035.04.1497635","volume":"35","author":"C Coronado","year":"2010","unstructured":"Coronado C, Galmarini CM, Alfaro V, Yovine A (2010) Elisidepsin. Drugs Fut 35:287\u2013296","journal-title":"Drugs Fut."},{"issue":"1","key":"60_CR10","first-page":"317","volume":"41","author":"C Teixido","year":"2012","unstructured":"Teixido C, Arguelaguet E, Pons B, Aracil M, Jimeno J, Somoza R et al (2012) ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. Int J Oncol 41(1):317\u2013324, Epub 2012\/04\/10","journal-title":"Int J Oncol"},{"key":"60_CR11","unstructured":"Elices M, Lepage DJ, Grant W, Alvarez E, Guillen MJ, Cuevas C, et al (2006) Activity of PM02734 against human breast and prostate tumors. AACR American Association for Cancer Research; 97th Annual Meeting; April 1\u20135, 2006. Washington, D.C. Abs. No 4712"},{"issue":"5","key":"60_CR12","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-012-1951-6","volume":"70","author":"R Salazar","year":"2012","unstructured":"Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C et al (2012) A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemother Pharmacol 70(5):673\u2013681, Epub 2012\/08\/29","journal-title":"Cancer Chemother Pharmacol"},{"key":"60_CR13","doi-asserted-by":"crossref","unstructured":"Bruce JY, Geary D, de las Heras B, Soto A, Garcia Paramio P, Yovine A et al (2008) Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations. ASCO American Society of Clinical Oncology, 44th Annual Meeting, May 30\u2013Jun 3, 2008. Chicago, Illinois. Abs. N\u00ba2513","DOI":"10.1200\/jco.2008.26.15_suppl.2513"},{"key":"60_CR14","doi-asserted-by":"crossref","unstructured":"Salazar R, Metges JP, Anthoney DA, Laus G, Maqueda MA, Goncalves A et al (2013) IMAGE, a randomized phase Ib\/II study of elisidepsin (E) as a single agent in pretreated advanced gastroesophageal (GE) cancer. 2013 Gastrointestinal Cancers Symposium, Jan 24\u201326, 2013. San Francisco, California. JClin Oncol vol 31(4 Supl): Abs N\u00ba92","DOI":"10.1200\/jco.2013.31.4_suppl.92"},{"key":"60_CR15","doi-asserted-by":"crossref","unstructured":"Goel S, Moran T, Coronado C, Viteri Ramirez S, Chaudhary I, Haroon Ghalib M et al (2012) Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors. ASCO American Society of Clinical Oncology, 48th Annual Meeting, Jun 1\u20135, 2012. Chicago, Illinois. J Clin Oncol. vol 30 (Supl 1) Abs N\u00ba 3093","DOI":"10.1200\/jco.2012.30.15_suppl.3093"},{"issue":"2","key":"60_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000341104","volume":"5","author":"R Salazar","year":"2012","unstructured":"Salazar R, Cuadra C, Gil-Martin M, Vandermeeren A, Alfaro V, Coronado C (2012) Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature. Case Rep Oncol 5(2):354\u2013358, Epub 2012\/07\/19","journal-title":"Case Rep Oncol"},{"key":"60_CR17","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events. Version 3.0. http: \/\/ctepcancergov\/forms\/ CTCAEv3pdf Accessed on 10 July 2008"},{"issue":"3","key":"60_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216, Epub 2000\/02\/03","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"60_CR19","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89(15):1138\u20131147, Epub 1997\/08\/06","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"60_CR20","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/rcm.2644","volume":"20","author":"J Yin","year":"2006","unstructured":"Yin J, Aviles P, Lee W, Ly C, Guillen MJ, Munt S et al (2006) Development of a liquid chromatography\/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma. Rapid Commun Mass Spectrom RCM 20(18):2735\u20132740, Epub 2006\/08\/22","journal-title":"Rapid Commun Mass Spectrom RCM"},{"issue":"11","key":"60_CR21","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol Off J Am Soc Clin Oncol 7(11):1748\u20131756, Epub 1989\/11\/01","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"60_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1023\/A:1008301522349","volume":"10","author":"CJ van Moorsel","year":"1999","unstructured":"van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE et al (1999) Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol Off J Eur Soc Med Oncol ESMO 10(4):441\u2013448, Epub 1999\/06\/17","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"60_CR23","unstructured":"Coronado C, Kahatt C, Szyldergemajn S, Iglesias JL, Florez A, Yovine A (2010) Transient isolated transaminase increases do not correlate with permanent clinical liver damage: phase I experience wih elisidepsin. 35th ESMO Congress, Milan, Italy 8\u201312 October 2010. Ann Oncol. Vol 21 (Supl 8) Abs. No 553 pages 180\u2013181"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0060-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-0060-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0060-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0060-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:48:33Z","timestamp":1678510113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-0060-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["60"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-0060-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]},"assertion":[{"value":"17 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}